|Bid||49.92 x 200|
|Ask||49.96 x 200|
|Day's range||49.15 - 51.00|
|52-week range||26.26 - 52.67|
|PE ratio (TTM)||-21.32|
|Earnings date||25 Oct 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||68.12|
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Controversy dimmed the excitement over the FDA’s decision last year to approve Sarepta Therapeutics’s (SRPT) Duchenne muscular dystrophy drug Exondys51. On Saturday, early-stage data regarding golodirsen was released at the 22nd International Annual Congress of the World Muscle Society. Today, some analysts are offering their take on what might be in store for Sarepta and at the FDA.
Sarepta Therapeutics Inc. shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a "compelling argument" for faster-than-normal approval ...
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
Barron's Andrew Bary has been a fan of Sarepta Therapeutics (SRPT) for a long time. Bary has remained bullish nearly every step of the way, most recently last month, when he argued that "soaring Sarepta can continue to stay hot," thanks to the possibility for an accelerated approval for a second Duchenne muscular dystrophy. For instance, Morgan Stanley's Matthew Harrison and team upgraded Sarepta to Overweight from Equal Weight with a $60 price target today.
Sarepta Therapeutics Inc. shares surged 7.5% in heavy morning trade Monday after the company was upgraded to overweight by Morgan Stanley with a $60 price target. Sarepta shares were valued at $48.68 as ...
Sarepta’s Duchenne muscular dystrophy drug was approved by the FDA despite a negative recommendation — sparking concerns about setting a precedent.
Sarepta flopped Friday after the FDA released details of patient deaths following treatment with its muscular dystrophy drug.
Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen and Acadia Pharmaceuticals all traded lower after investors found reports on their drugs on a database.
Sarepta Therapeutics Inc. shares declined as much as 8% in morning trade Friday on safety issues reported in the Food and Drug Administration's Adverse Events Reporting System (FAERS) for the company's ...
Sarepeta Therapeutics shares are down 4% this morning at $45.38 after trading below $43 amid investor concerns about data on a Food and Drug Administration web site showing 11 serious events including ...
Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy.
Sarepta Therapeutics reports positive results from a clinical trial of an experimental medicine for Duchenne muscular dystrophy.
Wall Street believes the biopharma's focus on developing treatments for rare neuromuscular diseases is paying off.
BURTON-ON-TRENT, England--(BUSINESSWIRE)-- Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access division and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have initiated a Managed Access Program ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced that the European Medicines Agency (EMA) validated the previously submitted Marketing Authorization application (MAA) for eteplirsen to treat Duchenne muscular dystrophy amenable to exon 51 skipping. Sarepta is seeking conditional approval of eteplirsen in the EU through the centralized procedure. Validation of the MAA confirms that the submission is accepted and starts the formal review process by the EMA’s Committee for Human Medicinal Products (CHMP).
The director of FDA's Center for Drug Evaluation and Research says the drug is part of a broader move toward patient-focused drug development.